Amino acid substitutions and deletions in the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can reduce the effectiveness of monoclonal antibodies (mAbs). In contrast, heterologous polyclonal antibodies raised against S protein, through the recognition of multiple target epitopes, have the potential to maintain neutralization capacities. XAV-19 is a swine glyco-humanized polyclonal neutralizing antibody raised against the receptor binding domain (RBD) of the Wuhan-Hu-1 Spike protein of SARS-CoV-2. XAV-19 target epitopes were found distributed all over the RBD and particularly cover the receptor binding motives (RBMs), in direct contact sites with the angiotensin converting enzyme-2 (ACE-2). Therefore, in Spike/ACE-2 interaction assays, XAV-19 showed potent neutralization capacities of the original Wuhan Spike and of the United Kingdom (Alpha/B.1.1.7) and South African (Beta/B.1.351) variants. These results were confirmed by cytopathogenic assays using Vero E6 and live virus variants including the Brazil (Gamma/P.1) and the Indian (Delta/B.1.617.2) variants. In a selective pressure study on Vero E6 cells conducted over 1 month, no mutation was associated with the addition of increasing doses of XAV-19. The potential to reduce viral load in lungs was confirmed in a human ACE-2 transduced mouse model. XAV-19 is currently evaluated in patients hospitalized for COVID-19-induced moderate pneumonia in phase 2a-2b (NCT04453384) where safety was already demonstrated and in an ongoing 2/3 trial (NCT04928430) to evaluate the efficacy and safety of XAV-19 in patients with moderate-to-severe COVID-19. Owing to its polyclonal nature and its glyco-humanization, XAV-19 may provide a novel safe and effective therapeutic tool to mitigate the severity of coronavirus disease 2019 (COVID-19) including the different variants of concern identified so far.
【저자키워드】 COVID-19, SARS-CoV-2, neutralization, variants, polyclonal antibody (PAb), 【초록키워드】 coronavirus disease, neutralizing antibody, Brazil, coronavirus, Mutation, Trial, Pneumonia, S protein, spike, severity, monoclonal antibody, variant, variants of concern, lung, Receptor binding domain, Angiotensin converting enzyme-2, ACE-2, Protein, Epitopes, Viral load, RBD, African, Wuhan, therapeutic, Patient, Effectiveness, Deletion, Efficacy and safety, Vero E6 cell, epitope, United Kingdom, moderate, Heterologous, mAbs, Live virus, Interaction, dose, Receptor binding, neutralization capacity, Contact, Safe, Vero E6, polyclonal antibody, acute respiratory syndrome, moderate-to-severe COVID-19, Substitution, South, selective, Wuhan-Hu-1, mitigate, effective, polyclonal, evaluate, assays, addition, evaluated, raised, conducted, demonstrated, the RBD, maintain, reduce, the Spike, transduced, patients hospitalized, 【제목키워드】 spike, target, Multiple, Against,